
    
      The study will be conducted under the real clinical practices in accordance with Korea Food
      and Drug Administration "Basic standard for reexamination of new drug".

      No vaccine will be provided and/or administered as part of this protocol, however only
      participants that has received AVAXIM 160U vaccine administered under the routine practice
      according to Summary of Product Characteristics will be part of the surveillance.
    
  